An observational study in Hypoxic Ischemic Encephalopathy of Newborn, Neonatal Encephalopathy and Premature Infant Disease, sponsored by University of Edinburgh. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 1 Day to 14 Weeks. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by University of Edinburgh · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hypoxia-Ischemia, Brain with a site in United Kingdom — 3 open to participants now, 5 under way, none of them phase 3. Hypoxia-Ischemia, Brain · United Kingdom.
Among the 16 studies in Hypoxia-Ischemia, Brain with a site in United Kingdom, this one is one of 2 that started in 2023, is one of 8 observational ones, and was the 14th registered.
261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.
Browse Hypoxia-Ischemia, Brain studies →3 of the 16 studies in Hypoxia-Ischemia, Brain with a site in United Kingdom are open now. Recruiting first, the newest first:
Medway NHS Foundation Trust · Sites in United Kingdom
Ages 16+ · Women only · Healthy volunteers
University of Michigan · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 2 days–17 yrs
Birmingham Women's NHS Foundation Trust · Sites in United Kingdom
Ages 0 min–8 wk · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.
This study: 1 Day to 14 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3
First in 2009; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 99 is above the median of 89 across 92 observational studies indexed under Hypoxia-Ischemia, Brain.
Median enrollment 53 across the 8 interventional studies, 195 across the 8 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.
University of Edinburgh has 1 study filed under Hypoxia-Ischemia, Brain — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypoxia-Ischemia, Brain with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05588960University of EdinburghInvestigating Cerebral Oxygenation in the Newborn | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Hypoxia-Ischemia, Brain with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this single centre observational study is to use near-infrared spectroscopy (NIRS) monitoring to investigate cerebral oxygenation in two groups of newborn infants who are at high risk of brain injury. The NIRS monitor used in this study will be the Masimo O3 regional oximeter with neonatal sensors.
Near-infrared spectroscopy (NIRS) monitoring uses near-infrared light to measure oxygen levels in the brain tissue (cerebral oxygenation). It provides information about blood flow to the brain and the balance between oxygen supply and demand in the brain tissue. It is non-invasive, safe and used routinely to monitor term and premature babies in the neonatal intensive care unit (NICU).
This study will recruit two groups of infants admitted to the NICU who are at risk of brain injury in the newborn period, namely:
In the term/near-term group, the primary aims of the study are:
In the preterm group, the primary aims of the study are:
TERM/NEAR-TERM GROUP
Hypoxic-ischaemic encephalopathy (HIE) is the most common cause of newborn brain injury in term and near-term infants. It is caused by a lack of oxygen supply or blood flow to the brain around the time of delivery. It is classified as mild, moderate or severe based on the symptoms present. Babies with moderate or severe HIE are treated with 3 days of cooling treatment (therapeutic hypothermia). This treatment protects the brain and reduces the risk of death or disability. However, despite this treatment some babies do not survive or develop life-long disabilities. Therefore, research into potential new treatments for HIE is ongoing.
Currently, the best tests available to detect brain injury and predict later outcome are magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) scans of the brain. However, these are only performed after therapeutic hypothermia is complete, between 5 to 15 days after birth. It would be advantageous if there was a tool that could identify brain injury earlier in the course, as this could facilitate identification of babies who may benefit most from new treatments in the future. Brain injury due to HIE can cause altered blood flow and oxygen levels in the brain, which can be detected by NIRS monitoring. Therefore, it is possible that NIRS monitoring could facilitate earlier detection of brain injury in this group. To understand this further, it is essential to further investigate the relationship between cerebral oxygenation measurements derived by NIRS monitoring and current markers of brain injury. Therefore, the first research question in this group is:
▪ How does cerebral oxygenation during and after therapeutic hypothermia (TH) for moderate to severe HIE relate to markers of brain injury detected on MRI and MRS scans performed between 5 to 15 days after birth?
Seizures are common in babies with HIE. Frequent or prolonged seizures are associated with higher risk of adverse outcomes. It is possible that seizures contribute to on-going injury to the brain due to disrupting the balance of oxygen supply and demand in the brain. This study aims to understand more about this by answering the following research question:
▪ How does cerebral oxygenation change during seizures in infants undergoing therapeutic hypothermia for moderate to severe HIE?
In this group, NIRS monitoring is used routinely in the study centre for all infants undergoing therapeutic hypothermia. Therefore, data from routine NIRS monitoring alongside other data collected as part of routine clinical care (clinical assessments, aEEG and MRI/MRS) will be analysed in a novel way to answer the research questions.
Routinely acquired clinical data will also be analysed to meet the following secondary objectives:
PRETERM GROUP
Although survival of infants born extremely prematurely (before 28 weeks of pregnancy) has improved over recent decades, these babies remain at high risk of neurodevelopmental disabilities due to brain injury or dysmaturation. The immature brain is vulnerable to fluctuations in cerebral blood flow and oxygenation, which may be detected by NIRS monitoring. In this group of infants, recognisable patterns of brain injury include intraventricular haemorrhage (bleeding into the fluid filled spaces in the brain) and periventricular leukomalacia (cysts in the brain tissue). These conditions can be detected by ultrasound scans of the brain which are performed routinely for all premature babies.
Skin-to-skin care, when an infant is nursed in direct skin-to-skin contact with a parent or carer, is commonly undertaken in the neonatal intensive care unit. There are many documented benefits for babies and their parents. Previous studies have investigated cerebral oxygenation during skin-to-skin care, however, these studies have not included infants with severe brain injury. This study seeks to understand whether more severe patterns of brain injury detected on cranial ultrasound affects cerebral oxygenation during skin-to-skin care by answering the following research question:
▪ Do changes in cerebral oxygenation during periods of skin-to-skin care versus flanking periods of incubator care differ in preterm infants with severe brain injury compared to infants without severe brain injury?
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that occurs in premature babies. It is diagnosed if a baby still requires extra oxygen or other breathing support at 36 weeks corrected gestational age (4 weeks before their due date). It is associated with brain dysmaturation and a higher chance of neurodevelopmental disabilities. It is possible that lower cerebral oxygenation levels contribute to brain dysmaturation in this group. Therefore, this study aims to answer the following research question:
▪ Does cerebral oxygenation and cerebral hypoxic burden (a measure of low oxygen levels in the brain accounting for severity and duration) differ in extremely preterm infants with bronchopulmonary dysplasia (BPD) compared to infants without BPD at 36 weeks corrected gestational age?
In the study centre, NIRS monitoring is routine for all infants born at less than 28 weeks for the first 72 hours after birth. Therefore, to answer the above research questions, NIRS monitoring will also be applied for additional periods out with routine clinical care for infants recruited to the study. No other changes to routine clinical care will be made for infants recruited to the study.
Data from routine NIRS monitoring for the first 72 hours after birth and from routine scans and neurodevelopmental follow up assessments will also be collected to fulfil the following secondary objectives:
▪ To compare cerebral oxygenation and cerebral hypoxic burden over the first 72 hours after birth to: worst grade of injury detected on routine screening cranial ultrasound scans and outcomes of neurodevelopmental assessments in infancy and at the age of 2 years.
This study will recruit a cohort of term/near-term and preterm infants who admitted to the neonatal intensive care unit at the Simpson Centre for Reproductive Health (Edinburgh, NHS Lothian, UK) and are at risk of brain injury or brain dysmaturation.
Potential participants will be identified through admission to the neonatal intensive care unit. Once eligibility is confirmed, a member of the research team will approach parents to discuss the study and invite the baby to enter the study.
Participants will be recruited over a 2 year period.
Preterm infants may be enrolled in more than one sub-study should their parents provide informed consent for this.
TERM/NEAR-TERM GROUP
INCLUSION CRITERIA:
Infants born at greater than or equal to 34 weeks gestational age undergoing therapeutic hypothermia as an intervention for moderate to severe neonatal encephalopathy. These infants will meet the following criteria for treatment:
EXCLUSION CRITERIA:
PRETERM GROUP
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort of term/near-term infants undergoing therapeutic hypothermia for moderate to severe HIE. Data collected from NIRS monitoring and other assessments/investigations that are part of routine clinical care. There are no additional study specific interventions or exposures for this group.
Cohort of infants born at less than 28 weeks gestational age. Data collected from NIRS monitoring, other physiological monitoring, cranial ultrasound scans and neurodevelopmental follow up assessments that are part of routine clinical care. This data will be analysed to fulfil secondary study objectives. There are no additional study specific interventions or exposures for this group.
Cohort of infants born at less than 28 weeks gestational age who are considered by clinical team to be suitable to undergo period of skin-to-skin care. Participants will undergo additional research-specific period(s) of NIRS monitoring before, during and after period(s) of skin-to-skin care. Participants with and without severe brain injury on cranial ultrasound will be recruited to allow comparison.
Device: Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)
Cohort of infants born at less than 28 weeks gestational age who will undergo an additional research-specific period of NIRS monitoring at 36 weeks corrected gestational age. Participants with and without bronchopulmonary dysplasia (BPD) will be recruited to allow comparison.
Device: Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)
Masimo O3 neonatal sensor will be applied: * At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition). * Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour. * For at least 1 hour after the participant is returned to their incubator (post-intervention condition). The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch.
Masimo O3 neonatal sensor will be applied: ▪ For 24 hours once the participant reaches 36 weeks corrected gestational age.
Term/Near-Term Group: Primary Outcome 1
Mean cerebral oxygenation calculated over 1 hour periods at pre-defined time points during therapeutic hypothermia and after completion of rewarming compared to presence/absence of brain injury on magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) performed between 5-15 days after birth. Brain injury will be defined as: * NICHD NRN MRI score of ≥2A * Lactate to n-acetylaspartate peak ratio of \>0.39 on MRS
Time frame: Birth-15 days
Term/Near-Term Group: Primary Outcome 2
Maximum change in cerebral oxygenation from baseline occurring during electrical seizures detected on aEEG and cerebral hypoxic burden (expressed in % hours) for any periods of cerebral hypoxia associated with seizures.
Time frame: Birth-5 days
Preterm Group - Skin-to-skin sub-study: Primary Outcomes
Change in mean cerebral oxygenation (calculated every 5 minutes) and in variability of cerebral oxygenation during a period of skin-to-skin care compared to periods of incubator care before (pre-intervention) and after (post-intervention) skin-to-skin care. These measures will be compared in infants with and without severe brain injury detected on routine cranial ultrasound scans. Severe brain injury will be defined as: * Grade III or IV intraventricular haemorrhage * Cystic periventricular leucomalacia
Time frame: 2.5 hours
Preterm Group - BPD sub-study: Primary Outcomes
Mean cerebral oxygenation measured over a 24-hour period at 36 weeks corrected gestational age and cerebral hypoxic burden (expressed in % hours) of any periods of cerebral hypoxia over this 24-hour epoch. These measures will be compared in infants with and without a diagnosis of bronchopulmonary dysplasia. Bronchopulmonary dysplasia will be defined as the need for any additional respiratory support (including supplementary oxygen) at 36 weeks corrected gestational age.
Time frame: 24 hours
Term/Near-Term Group: Secondary Outcome 1
Outcome of General Movements Assessment at term and between 12 to 15 weeks post-term age. High-risk patterns will be defined as cramped synchronised pattern (term equivalent age) and absent fidgety movements (12-15 weeks post-term).
Time frame: Birth-12 to 15 weeks
Term/Near-Term Group: Secondary Outcome 2
Outcome at 2 years of age. Adverse outcome will be defined as death or moderate-severe neurodevelopmental disability as follows: * Moderate: Cerebral palsy with GMFCS level 2; Bayley III composite motor/congitive/language score of \<85; hearing impairment without need for amplification; persistent seizure disorder. * Severe: Cerebral palsy with GMFCS level ≥3; Bayley III composite motor/cognitive/language score of \<70; hearing impairment requiring hearing aids; blindness.
Time frame: 2 years
Preterm Group: Secondary Outcome 1
Comparison of mean cerebral oxygenation and cerebral hypoxic burden (expressed in % hours) for the first 72 hours after birth to findings of routine cranial ultrasound scans at: * 1 day after birth * 2 days after birth * 3 days after birth * 7 days after birth * Term equivalent age
Time frame: Birth-max 14 weeks
Preterm Group: Secondary Outcome 2
Comparison of mean cerebral oxygenation and cerebral hypoxic burden (expressed in % hours) for the first 72 hours after birth to outcomes of General Movements Assessment at term equivalent age and between 12 to 15 weeks post-term age. High-risk patterns will be defined as cramped synchronised pattern (term equivalent age) and absent fidgety movements (12-15 weeks post-term).
Time frame: Birth-12 to 15 weeks
Preterm Group: Secondary Outcome 3
Comparison of mean cerebral oxygenation and cerebral hypoxic burden (expressed in % hours) for the first 72 hours after birth to outcome at 2 years corrected gestational age. Adverse outcome will be defined as death or moderate-severe neurodevelopmental disability as follows: * Moderate: Cerebral palsy with GMFCS level 2; Bayley III composite motor/congitive/language score of \<85; hearing impairment without need for amplification; persistent seizure disorder. * Severe: Cerebral palsy with GMFCS level ≥3; Bayley III composite motor/cognitive/language score of \<70; hearing impairment requiring hearing aids; blindness.
Time frame: 2 years
Plan to share: Yes — Following completion of the study and after primary publications by the study team, all collected anonymous IPD will be shared in line with the FAIR principles (findable, accessible, interoperable and resuable). Parents will have the option to opt out of their child's anonymous data being shared for the purposes of further research at the time of consent. Data will be made available through DataShare, a data respository run by The University of Edinburgh. This will be maintained indefinitely by the University of Edinburgh Data Library staff. Associated metadata will be created in Pure (the University's Current Research Information System) which will be linked to the dataset in DataShare.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data will be shared after primary publications by the study team, which are likely to take 6-12 months after the end of the project.
Access criteria: When data is deposited in DataShare, a DOI will be acquired. This DOI will be used in all communications regarding the data, for example, publications and presentations. A data access statement will be included in all publications. Data on DataShare will be licensed under a CC BY license. A metadata will be created in Pure (the University's Current Research Information System) which will be linked to the dataset in DataShare. Pure metadata records are published to Edinburgh Research Explorer, which provides a searchable public view of the University's research activities.
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jan 2027, 42 months after the start.
Of 46 non-industry observational studies under Hypoxia-Ischemia, Brain, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 20. This study's planned 42 months is close to that.
Counting every sponsor, half of 50 studies reached it within 43 months; a quarter within 20.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.